Oral phentolamine (Vasomax)

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Urology

Background:

• Phentolamine mesilate, an alpha-adrenergic antagonist, has a long history of clinical use.
• Previously marketed orally, it was approved for pheochromocytoma management and evaluated for various conditions.
• Vasomax represents a new preparation of phentolamine for on-demand erectile dysfunction treatment.

Purpose of the Study:

• To review the potential of Vasomax (phentolamine mesilate) for treating mild to moderate erectile dysfunction.
• To discuss the pharmacological actions and historical clinical applications of phentolamine.
• To evaluate the suitability of phentolamine for on-demand erectile dysfunction therapy.

Main Methods:

• Review of existing clinical data and pharmacological properties of phentolamine.
• Analysis of phentolamine's mechanism of action as an alpha-adrenergic antagonist and vasodilator.
• Examination of historical use and adverse event profiles of oral phentolamine.

Main Results:

• Phentolamine is a potent vasodilator acting on muscular-walled vessels, possibly via potassium channel inhibition.
• Past clinical responses for various indications were variable, with significant adverse events including hypotension and gastrointestinal issues.
• The review focuses on phentolamine's application in a new preparation for erectile dysfunction.

Conclusions:

• Phentolamine mesilate demonstrates vasodilatory properties relevant to erectile dysfunction.
• Historical data suggests variable efficacy and potential adverse events that need consideration.
• Further evaluation of this new preparation for on-demand erectile dysfunction treatment is warranted.